View in EDS PDF Full Text

VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma.

Saved in:
Bibliographic Details
Title: VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma.
Authors: He HX; State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Gao Y; State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Fu JC; State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhou QH; Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China., Wang XX; State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Bai B; State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Li PF; State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Huang C; State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Rong QX; State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Ping LQ; State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., He YX; State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Mao JY; State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Chen X; Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China., Huang HQ; State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Source: Oncoimmunology [Oncoimmunology] 2021 Apr 07; Vol. 10 (1), pp. 1907059. Date of Electronic Publication: 2021 Apr 07.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: Electronic Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2162-402X
DOI:10.1080/2162402X.2021.1907059